Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

239.99 +2.20 (+0.93%)

Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Johnson & Johnson Is A Resilient Blue-Chip Stock And It Just Hit New All-Time Highs ↗

February 06, 2026

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs.

Via Talk Markets

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

February 06, 2026

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from...

Via Barchart.com

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? ↗

February 04, 2026

Via The Motley Fool

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition

February 05, 2026

In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for...

Via MarketMinute

Topics Supply Chain

Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)

February 05, 2026

February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...

Via Finterra

Topics Product Recall World Trade

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery

February 02, 2026

As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3...

Via TokenRing AI

Topics Artificial Intelligence

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Via The Motley Fool

Topics Intellectual Property

All It Takes Is $13,000 Invested in Each of These 2 Dividend Kings to Help Generate $1,000 in Passive Income in 2026 ↗

February 01, 2026

Consumer staples stocks being out of favor is an impeccable buying opportunity for value investors.

Via The Motley Fool

Topics Earnings

3 Vanguard ETFs to Buy to Protect Your Portfolio from a Potential Stock Market Crash ↗

February 01, 2026

These Vanguard funds won't necessarily keep you from losing money if the market crashes. But they can help cushion the blow.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗

January 31, 2026

These market giants make great long-term investments.

Via The Motley Fool

1 Super-Safe High-Yield Dividend King Stock to Buy Even if There's a Stock Market Sell-Off in 2026 ↗

January 31, 2026

Near a 12-year low, Kimberly-Clark may be one of the best deep value stocks for income investors to buy in 2026.

Via The Motley Fool

Topics Artificial Intelligence Economy World Trade

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗

January 30, 2026

Johnson & Johnson is a picture of stability.

Via The Motley Fool

Topics Intellectual Property

Economic Alarm Bells: LEI Index Slips 0.3% as US Economy Navigates a Fragile 2026 Start

January 30, 2026

The Conference Board’s Leading Economic Index (LEI) recorded a 0.3% slip in its latest reading, signaling a cooling trajectory for the United States economy as it enters the new year. This downturn,...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

January 30, 2026

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Via Barchart.com

Topics ETFs World Trade

TSM or NVDA? ↗

January 29, 2026

Taiwan Semiconductor recently put up stellar fourth-quarter numbers, signaling that we've yet to reach peak AI demand. Are we in for another banner year in 2026?

Via The Motley Fool

Topics Artificial Intelligence

The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life

January 28, 2026

In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic...

Via TokenRing AI

Topics Artificial Intelligence Economy

Boston Scientific to Acquire Penumbra for $14.5 Billion in Massive MedTech Consolidation

January 28, 2026

MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra...

Via MarketMinute

Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years ↗

January 28, 2026

And that won't be the end of their growth stories.

Via The Motley Fool

Topics Credit Cards

3 Dividend Stocks to Hold for the Next 20 Years ↗

January 28, 2026

These aren't high-growth businesses, but they're as reliable as they come.

Via The Motley Fool

JNJ Stock Rises On Fresh FDA Approval For Multiple Myeloma Drug ↗

January 27, 2026

FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Via Stocktwits

The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants

January 27, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN)...

Via MarketMinute

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Topics Earnings Economy Government

The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge

January 26, 2026

As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States...

Via MarketMinute

Topics Artificial Intelligence Economy

Johnson & Johnson At 52‑Week High: Momentum, Fundamentals And An Earnings Window ↗

January 26, 2026

Johnson & Johnson is trading at a 52-week high due to strong momentum and positive sentiment, with upcoming earnings set to test the sustainability of its current gains.

Via Talk Markets

Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors ↗

January 25, 2026

Via MarketBeat

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.